CAPTAIM

The development of mRNA vaccines against cancer could revolutionize oncology by enabling highly personalized therapies. Pioneer Fellow Massimo Saini and his team at CAPTAIM are working on an advanced liquid biopsy technology. This method uses modern blood analysis to provide crucial information for tailored cancer treatments. Particularly beneficial for patients with tumors of difficult accessibility, CAPTAIM offers a less invasive and more accurate alternative to traditional biopsies, leading to more effective treatments and improved quality of life.